The Efficacy and Safety of IBI363 in Solid Tumors
The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3 dose-escalation design, with a preference for enrolling subjects with advanced non-small cell lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven cohorts.
Advanced Solid Tumor
DRUG: IBI363|DRUG: IBI363|DRUG: IBI363|DRUG: IBI363|DRUG: IBI363
Adverse Event, Number of participants experiencing clinical and laboratory adverse events (AEs), Up to 90 days post last dose|ORR, Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects, 1 year
The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3 dose-escalation design, with a preference for enrolling subjects with advanced non-small cell lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven cohorts. All the research data were collected follow the SAP.